Narinder Nangia Selected Research

3,3'- di- (N- cyclopropylmethyl- 4,5- epoxy- 14- hydroxymorphinan- 6- one- 3- yl)carbonate

1/2020

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Narinder Nangia Research Topics

Disease

4	Opioid-Related Disorders (Opiate Addiction) 12/2020 - 01/2018
3	Major Depressive Disorder (Major Depressive Disorders) 01/2020 - 01/2019
2	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020 - 01/2018
2	Schizophrenia (Dementia Praecox) 01/2020 - 01/2019
1	Thrombotic Microangiopathies 01/2022
1	Relapsing-Remitting Multiple Sclerosis 11/2020
1	Weight Gain 01/2020

Drug/Important Bio-Agent (IBA)

5	Buprenorphine (Subutex)FDA LinkGeneric 12/2020 - 01/2019
5	Opioid Analgesics (Opioids)IBA 01/2020 - 01/2018
4	Naltrexone (ReVia)FDA LinkGeneric 12/2020 - 01/2018
4	3-carboxamido-4-hydroxynaltrexoneIBA 01/2020 - 01/2019
2	Olanzapine (Zyprexa)FDA Link 01/2020 - 01/2019
2	Narcotic Antagonists (Opioid Antagonists)IBA 01/2020 - 01/2019
1	narsoplimabIBA 01/2022
1	Serine (L-Serine)FDA Link 01/2022
1	Mannose-Binding Lectin (Mannan-Binding Lectin)IBA 01/2022
1	diroximel fumarateIBA 11/2020
1	FumaratesIBA 11/2020
1	Delayed-Action PreparationsIBA 01/2020
1	3,3'- di- (N- cyclopropylmethyl- 4,5- epoxy- 14- hydroxymorphinan- 6- one- 3- yl)carbonateIBA 01/2020
1	Moxifloxacin (Avelox)FDA Link 01/2020
1	Antipsychotic Agents (Antipsychotics)IBA 01/2020

Therapy/Procedure

2	Injections 12/2020 - 01/2018
1	Therapeutics 01/2022
1	Hematopoietic Stem Cell Transplantation 01/2022